-ELI-002 2P was safe with demonstrated ctND and serum tumor biomarker reduction in 79% of patients and clearance in 21% of patients. as well as notable mutant KRAS-specific T cell immune responses in 8-% of patients Results suggest that evaluation of cDNA reduction/clearance in resectable PDAC patients who are cDNA-positive after curative intent treatment is an effective method to accurately determine improved RFS. The gene discussed is KRAS; the disease is neoplasm.